Culture Medium, Per Se Patents (Class 435/404)
-
Patent number: 8252557Abstract: Disclosed is a culture medium for culturing an animal cell, which is characterized by containing a peptide comprising, as a constituent unit, an amino acid residue selected from the amino acid group consisting of serine, tyrosine and cysteine. The culture medium is suitable for the high level production of a protein by an animal cell.Type: GrantFiled: October 27, 2009Date of Patent: August 28, 2012Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Satoshi Katayama, Shouhei Kishishita, Kunihiko Kodaira, Makoto Sadamitsu, Yoshinori Takagi, Hiroki Matsuda
-
Patent number: 8252591Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.Type: GrantFiled: May 6, 2005Date of Patent: August 28, 2012Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's HospitalInventors: Tan A. Ince, Robert A. Weinberg
-
Publication number: 20120214204Abstract: The invention relates to cell culture media optimized for exposure to ultraviolet C (UVC) light exposure and related methods.Type: ApplicationFiled: February 17, 2012Publication date: August 23, 2012Applicant: AMGEN INC.Inventors: Roger HART, Robert Michael Boychyn
-
Publication number: 20120214234Abstract: The present invention provides a method for producing iPS cells, comprising reacting cells with at least one connexin inhibitor and at least one TGF? signaling inhibitor; iPS cells comprising at least one connexin inhibitor; an iPS cell inducer comprising at least one inhibitor selected from the group consisting of connexin inhibitors and TGF? signaling inhibitors; a medium for inducing iPS cells, comprising at least one inhibitor selected from the group consisting of connexin inhibitors and TGF? signaling inhibitors; and a kit for inducing iPS cells, comprising at least one inhibitor selected from the group consisting of connexin inhibitors and TGF? signaling inhibitors.Type: ApplicationFiled: December 27, 2011Publication date: August 23, 2012Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATIONInventors: Tetsuro TAKAMATSU, Ping DAI
-
Patent number: 8247226Abstract: The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.Type: GrantFiled: June 23, 2011Date of Patent: August 21, 2012Assignee: Sanofi Pasteur Vaxdesign Corp.Inventors: Selva Sukumar, Mohey Eldin M. El Shikh, John G. Tew, Guzman Sanchez-Schmitz, Donald Drake, III, Luis Mosquera, Conan Li, Anatoly M. Kachurin, Russell Higbee, Heather Fahlenkamp, Eric Mishkin, William L. Warren
-
Publication number: 20120207705Abstract: A process for preparing a conditioned cell culture medium is provided. The process comprises a) culturing eukaryotic cells in a growth medium having a composition effective to support cell growth; b) separating the cultured cells from the growth medium; and c) maintaining the cultured cells in a basal medium having a composition suitable to maintain cell viability, but not to support substantial cell growth. The cells are preferably dermal sheath, dermal papilla or dermal fibroblast cells. The compositions are useful as pharmaceutical compositions, especially for wound healing.Type: ApplicationFiled: September 16, 2010Publication date: August 16, 2012Inventor: Bhupendra Vallabh Kara
-
Publication number: 20120202291Abstract: Fully defined media that support pluripotent cell viability, proliferation, cloning, and derivation, as well as methods and compositions including these media are described. Methods for deriving iPS cells from adult individuals under defined, xeno-free conditions are also described.Type: ApplicationFiled: August 5, 2011Publication date: August 9, 2012Inventors: Guokai Chen, James A. Thomson
-
Publication number: 20120196367Abstract: A method for culturing a number of cells includes the following steps. A culture medium is provided. The culture medium has a carbon nanotube structure and a hydrophilic layer. The hydrophilic layer is formed on a surface of the carbon nanotube structure. A polar layer is formed on a surface of the hydrophilic layer away from the carbon nanotube structure. The cells are seeded and cultured on the polar layer.Type: ApplicationFiled: January 13, 2012Publication date: August 2, 2012Applicants: HON HAI PRECISION INDUSTRY CO., LTD., TSINGHUA UNIVERSITYInventors: CHEN FENG, LI FAN, WEN-MEI ZHAO
-
Publication number: 20120196368Abstract: A culture medium includes a carbon nanotube structure and a hydrophilic layer. The culture medium is capable of culturing at least one neuron. The hydrophilic layer has a polar surface and is located on a surface of the carbon nanotube structure. The polar surface is located on a surface of the hydrophilic layer away from the carbon nanotube structure, and has a polarity attracted to a polarity of the at least one neuron.Type: ApplicationFiled: January 13, 2012Publication date: August 2, 2012Applicants: HON HAI PRECISION INDUSTRY CO., LTD., TSINGHUA UNIVERSITYInventors: CHEN FENG, LI FAN, WEN-MEI ZHAO
-
Publication number: 20120196369Abstract: A method for forming a culture medium includes the following steps. A carbon nanotube structure is provided. A hydrophilic layer is formed on a surface of the carbon nanotube structure. The hydrophilic layer is polarized to form a polar surface on the hydrophilic layer. A number of neurons are formed on the polar surface of the hydrophilic layer.Type: ApplicationFiled: January 13, 2012Publication date: August 2, 2012Applicants: HON HAI PRECISION INDUSTRY CO., LTD., TSINGHUA UNIVERSITYInventors: CHEN FENG, LI FAN, WEN-MEI ZHAO
-
Patent number: 8232075Abstract: This invention relates to methods for rationally designing cell culture media for use in cell cultures, e.g., cell cultures employed in polypeptide production; cell culture media designed with the disclosed methods; methods of producing a polypeptide of interest, e.g., an antibody, using such media; polypeptides produced using the methods and media disclosed herein; and pharmaceuticals compositions containing such polypeptides. The rationally designed media contain a concentration of an amino acid that is calculated for use in cell mass, a concentration of the amino acid that is calculated for use in cell maintenance, and a concentration of the amino acid that is calculated for incorporation into the polypeptide of interest.Type: GrantFiled: November 8, 2007Date of Patent: July 31, 2012Assignee: Wyeth LLCInventors: Yen-Tung Luan, Wenge Wang, Ryan Nolan, Denis Drapeau
-
Patent number: 8227246Abstract: This invention provides an isolated disc stem cell population, compositions, and methods of obtaining and growing the same. Moreover, this invention provides an isolated discosphere, compositions, and methods of obtaining and growing the same. An artificial disc containing the cells of the present invention is provided together with methods of making the same. This invention also provides a method of treating a subject having a herniated disc utilizing the cells and methods of the invention.Type: GrantFiled: July 7, 2008Date of Patent: July 24, 2012Assignee: DiscgenicsInventors: Valery Kukekeov, Christopher Duntsch, Tatyana Igantova
-
Publication number: 20120178166Abstract: Fully defined media that support pluripotent cell viability, proliferation, cloning, and derivation, as well as methods and compositions including these media are described. Methods for deriving iPS cells from adult individuals under defined, xeno-free conditions are also described.Type: ApplicationFiled: December 30, 2011Publication date: July 12, 2012Inventors: Guokai Chen, James A. Thomson
-
Publication number: 20120171766Abstract: The present invention relates to a medium composition comprising neuropeptide Y, effective for proliferation and maintenance of undifferentiated pluripotent stem cells, and a method for culturing undifferentiated pluripotent stem cells using the same. The present invention improves the culture conditions for undifferentiated pluripotent stem cells, and ultimately, the present invention can be effectively used for the development of large-scale culture systems, thereby acquiring clinically applicable pluripotent stem cells. Further, the present invention relates to a dedifferentiation medium composition comprising neuropeptide Y (NPY), and a method for inducing dedifferentiation (or reprogramming) using the same. The present invention improves the culture conditions for dedifferentiation and contributes to develop technology of producing clinically applicable induced pluripotent stem cells, thereby being used for the development of stem cell therapy.Type: ApplicationFiled: June 16, 2010Publication date: July 5, 2012Inventors: Yee Sook Cho, Mi-Young Son
-
Patent number: 8211699Abstract: The present invention relates to cell culture methods and compositions that are essentially serum-free and comprise a basal salt nutrient solution and an ErbB3 ligand.Type: GrantFiled: August 13, 2007Date of Patent: July 3, 2012Assignee: ViaCyte, Inc.Inventors: Allan J. Robins, Thomas C. Schulz
-
Publication number: 20120156192Abstract: The present invention relates to methods and uses of cells for the prevention and treatment of a wide variety of diseases and disorders and the repair and regeneration of tissues and organs using low passage and extensively passaged in vitro cultured, self-renewing, colony forming somatic cells (CF-SC). For example, adult bone marrow-derived somatic cells (ABM-SC), or compositions produced by such cells, are useful alone or in combination with other components for treating, for example, cardiovascular, neurological, integumentary, dermatological, periodontal, and immune mediated diseases, disorders, pathologies, and injuries.Type: ApplicationFiled: January 12, 2012Publication date: June 21, 2012Applicant: Garnet Biotherapeutics, Inc.Inventors: Gene KOPEN, Joseph WAGNER, Vanessa RAGAGLIA, Baron HEIMBACH, Richard S. GORE
-
Publication number: 20120156783Abstract: A method for continuously preparing a medium formulation mixes a diluent with a plurality of chemically incompatible concentrate solutions in such a manner that none of the ingredients of the concentrate solutions chemically react in an adverse manner. The method utilizes a static mixing chamber to add the concentrate solutions to the diluent stream sufficiently in advance of one another so that adverse chemical reactions do not occur. The method also adjusts a pH level of the diluent prior to adding any of the concentrate solutions to the diluent.Type: ApplicationFiled: October 26, 2011Publication date: June 21, 2012Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: James Kubiak, Todd A. Battistoni, David W. Jayme
-
Publication number: 20120149107Abstract: The invention relates to a process for the culturing of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture.Type: ApplicationFiled: February 15, 2012Publication date: June 14, 2012Applicant: DSM IP ASSETS B.V.Inventors: Gerben Meile Zijlstra, Robert Patrick Hof, Jacob Schilder
-
Patent number: 8198084Abstract: The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.Type: GrantFiled: June 14, 2005Date of Patent: June 12, 2012Assignee: Life Technologies CorporationInventors: Stephen F. Gorfien, Richard M. Fike, Glenn P. Godwin, Joyce L. Dzimian, David A. Epstein, Dale Gruber, Don McClure, Paul J. Price
-
Patent number: 8192951Abstract: An improved system for large scale production of proteins and/or polypeptides in cell culture is provided. In accordance with the present invention, cells expressing the protein or polypeptide of interest are grown in media that comprise a glycolysis-inhibiting substance. Additionally and/or alternatively, cells expressing the protein or polypeptide of interest are grown in media in which glutamine is limited. The use of such a system allows high levels of protein or polypeptide production and lessens accumulation of undesirable metabolic waste products such as lactate. Proteins and polypeptides expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical, immunogenic, agricultural or other commercial compositions.Type: GrantFiled: November 2, 2007Date of Patent: June 5, 2012Assignee: Wyeth LLCInventors: Wenge Wang, Yen Tung Luan
-
Patent number: 8187881Abstract: The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.Type: GrantFiled: December 1, 2009Date of Patent: May 29, 2012Assignee: Stemnion, Inc.Inventors: Charlotte A. Smith, Catherine J. Trumpower, Vivienne S. Marshall
-
Publication number: 20120129727Abstract: The present invention relates to methods of selecting and developing a chemically defined media (“CDM”) for use in the manufacture of biological products. In particular, the present invention is directed to screening methods to determine cell culture technique media supplement blends with enhanced performance characteristics. The present invention is also directed to identifying CDM supplement blends that demonstrate significant increases in harvest titer and/or viable cell density.Type: ApplicationFiled: November 4, 2011Publication date: May 24, 2012Applicant: Abbott LaboratoriesInventors: Patrick Hossler, Christopher Racicot, Sean McDermott, John C. Fann
-
Patent number: 8183297Abstract: The invention relates to a device for selecting stem cells with a serum free medium for amplification of stem cells. The invention also relates to a method of treating or preventing diseases caused by cancer-related stem cells. The invention further provides a method of enhancing radiosensitivity of cancer-related stem cells comprising radiotherapy with resveratrol, and the cancer-related stem cell has stronger drug resistance. The present invention further provides that resveratrol promotes differentiation and inhibits teratoma/tumor formation in induced pluripotent stem cells (iPS) and embryonic stem cells.Type: GrantFiled: July 10, 2009Date of Patent: May 22, 2012Assignee: Taipei Veterans General HospitalInventors: Shih-Hwa Chiou, Tsung-Yun Liu, Tung-Hu Tsai, Jeng-Fan Lo, Yi-Ping Yang, Fu-Ting Tsai, Yu-Chih Chen, Chian-Shiu Chien
-
Patent number: 8183043Abstract: A modified sol-gel material and method of making the same is provided herein. More particularly, sol-gels disclosed herein have been modified to have one or more bioactive peptides covalently bound to the surface of the sol-gel. In one embodiment the peptide presenting sol-gels are prepared as thin film coatings and in a further embodiment the sol-gels are combined with living cells. The present disclosure is also directed to a novel one vessel reaction process for preparing the sol-gel-based peptide material.Type: GrantFiled: October 11, 2007Date of Patent: May 22, 2012Assignee: Purdue Research FoundationInventors: Jenna Leigh Rickus, Sabrina S. Jedlicka
-
Publication number: 20120121553Abstract: A population of progenitor cells and methods for obtaining and culturing the progenitor cells, that are useful in fields including regenerative medicine (tissue regeneration), transplantation, and cancer research.Type: ApplicationFiled: December 9, 2011Publication date: May 17, 2012Applicant: ORGAN RECOVERY SYSTEMS, INC.Inventor: Nancy L. PARENTEAU
-
Publication number: 20120107936Abstract: Methods of preparing pancreatic islets that may comprise pancreatites are provided. The methods may involve subjecting a pancreas and/or pieces thereof to disruption, such as, for example, an enzyme digest, and seeding the recovered cellular product comprising islets in a culture medium comprising at least a detectable amount of endocrine tissue and/or exocrine tissue.Type: ApplicationFiled: October 21, 2011Publication date: May 3, 2012Applicant: CELL & TISSUE SYSTEMS, INC.Inventors: Michael J. TAYLOR, Simona C. BAICU
-
Publication number: 20120100568Abstract: A serum-free medium for inducing and reprogramming somatic cells into induced pluripotent stem cells (iPS) quickly with high efficiency, and the method using thereof for inducing and reprogramming somatic cells without feeder are provided, wherein the rate and efficiency of whole process of inducing and reprogramming are greatly improved. The uses of the medium in inducing pluripotent stem cells, and the uses in the method for screening compounds, especially in the method for high throughput screening compounds are further provided.Type: ApplicationFiled: September 30, 2009Publication date: April 26, 2012Applicant: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCESInventors: Duanqing Pei, Jiekai Chen, Jing Liu
-
Patent number: 8158421Abstract: The present invention provides a method of enhancing the efficiency of differentiation of hES cells into cardiomyocytes which method comprises incubating the cells under serum free conditions. The method typically includes providing cells that induce cardiomyocyte differentiation by cell to cell contact. Differentiation to cardiomyocytes can occur via two routes, namely by spontaneous differentiation and by induced differentiation. Without wishing to be bound by theory the present inventors hypothesize that, in the case of induced differentiation, END-2 cells, for instance, are needed for aggregation to cause local high cell densities and in inducing differentiation of nascent mesoderm. This second step could be enhanced in any human embryonic stem cell line leading to the prediction that it will work in lines other than hES. In cell lines that undergo spontaneous differentiation, it is hypothesized that local induction of embryoid bodies in endoderm occurs.Type: GrantFiled: June 1, 2004Date of Patent: April 17, 2012Assignee: ES Cell International Pte LtdInventors: Robert Passier, Christine Lindsay Mummery
-
Publication number: 20120087899Abstract: Heparan sulphate from bone marrow stroma is disclosed together with the use of heparan sulphate from bone marrow stroma in the differentiation and/or lineage commitment of stem cells.Type: ApplicationFiled: October 6, 2011Publication date: April 12, 2012Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Simon Cool, Victor Nurcombe
-
Publication number: 20120088299Abstract: Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hamiones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.Type: ApplicationFiled: November 2, 2011Publication date: April 12, 2012Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Zhengxing Qu, Chien-Hsing Chang, Edmund A. Rossi, Jeng-Dar Yang, Diane Nordstrom
-
Publication number: 20120088303Abstract: The invention relates to preparing and/or supplementing a cell or tissue culture medium. In particular, said invention relates to a serum-free and/or protein-free cell culture medium comprising peptide fractions isolated from rapseeds, in particular rapseeds cakes. A method for the production of a cell culture comprising said peptide fractions and for the use thereof is also disclosed.Type: ApplicationFiled: July 1, 2011Publication date: April 12, 2012Inventors: Annie Marc, Jean-Louis Goergen, Bérangère Farges-Haddani
-
Publication number: 20120088729Abstract: Disclosed are compositions and methods of making non-glycosylated transferrin protein in transgenic monocot plants.Type: ApplicationFiled: May 6, 2011Publication date: April 12, 2012Inventors: Deshui Zhang, Ning Huang, Diane Phuong Nguyen, Paula Bryan
-
Patent number: 8153429Abstract: The present invention relates to cell culture methods and compositions that are essentially serum-free and comprise a basal salt nutrient solution and an ErbB3 ligand.Type: GrantFiled: February 23, 2007Date of Patent: April 10, 2012Assignee: ViaCyte, Inc.Inventors: Allan J. Robins, Thomas C. Schulz
-
Patent number: 8153430Abstract: The invention is directed to methods related to surgery, for example gastrointestinal surgery. In particular, the invention is methods of treating fistulae, promoting accelerated healing of anastomoses and preventing failure of anastomoses. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination.Type: GrantFiled: July 2, 2008Date of Patent: April 10, 2012Assignee: Stemnion, Inc.Inventors: Linda O. Palladino, Diana L. Clarke, Vivienne S. Marshall, Charlotte A. Smith, Martin C. Robson
-
Publication number: 20120077271Abstract: Fetal blood multi-lineage progenitor cells that are capable of a wide spectrum of transdifferentiation are described, as well as methods of differentiating the progenitor cells into chondrocytes.Type: ApplicationFiled: November 30, 2011Publication date: March 29, 2012Inventor: Daniel P. Collins
-
Publication number: 20120070407Abstract: There is disclosed the use of a composition for promoting neuronal growth of neurons in tissues of the central or peripheral nervous system. There is also disclosed a method for inducing proliferation or differentiation of neuronal cells.Type: ApplicationFiled: March 29, 2010Publication date: March 22, 2012Inventors: Michel Maurice Jacques Lazdunski, Catherine Louise Heurteaux, David Picard
-
Publication number: 20120070896Abstract: [Object] To provide a technology for production of safer iPS cells and to provide a more efficient technology for culturing iPS cells. [Solving Means] Induced pluripotent stem cells are produced from human somatic cells by co-culturing human somatic cells having a reprogrammed nucleus with human cells as feeder cells. Induced pluripotent stem cells are produced from somatic cells by co-culturing somatic cells having a reprogrammed nucleus with autologous cells as feeder cells. Induced pluripotent stem cells are cultured with culture supernatant of somatic cells.Type: ApplicationFiled: May 28, 2010Publication date: March 22, 2012Applicant: Kyoto UniversityInventors: Shinya Yamanaka, Kazutoshi Takahashi
-
Publication number: 20120064621Abstract: The present invention provided cell culture compositions capable of producing fusion polypeptides that bind vascular endothelial growth factor (VEGF). The cell culture compositions of the invention comprise cells which contain an expression vector comprising a nucleic acid molecule encoding a fusion polypeptide that binds VEGF. The fusion polypeptides may comprise a VEGF receptor component having immunoglobulin-like (Ig) domain 2 of a first VEGF receptor, an Ig domain 3 of a second VEGF receptor, and a multimerizing component.Type: ApplicationFiled: May 13, 2011Publication date: March 15, 2012Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Nicholas J. Papadopoulos, Samuel Davis, George D. Yancopoulos
-
Patent number: 8133580Abstract: The invention relates to an article comprising a coating, which coating comprises at least two layers, of which the inner layer is a primer layer, comprising a supporting polymer network which is composed of a supporting polymer selected from the group consisting of polyethers and polythioethers, including copolymers thereof, the supporting network optionally comprising a functional non-ionic hydrophilic polymer entangled in the supporting polymer network; and the outer layer is a functional layer comprising a functional non-ionic hydrophilic polymer and a polyelectrolyte.Type: GrantFiled: December 11, 2006Date of Patent: March 13, 2012Assignee: DSM IP Assets B.V.Inventors: Aylvin Jorge Angelo Athanasius Dias, Guido Joseph Elisabeth Hensen, Johannes Wilhelmus Belt, Marnix Rooijmans, Nicolaes Hubertus Maria De Bont, Edwin Peter Kennedy Currie
-
Publication number: 20120058561Abstract: The disclosure provides methods and compositions useful for culturing stem cell including embryonic stem cells, adult stem cells, and embryonic germ cells.Type: ApplicationFiled: April 13, 2010Publication date: March 8, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor: Noboru Sato
-
Patent number: 8129145Abstract: An improved system for large scale production of glycoproteins in cell culture is provided. In accordance with the present invention, cells expressing a glycoprotein are grown in media that contain manganese at a concentration of between approximately 10 and 600 nM. The use of such a system allows production of a glycoprotein with an increased glycosylation pattern and/or a glycosylation pattern that more accurately reflects the glycosylation pattern of the naturally occurring glycoprotein. A glycoprotein expressed in accordance with the present invention may be advantageously used in the preparation of pharmaceutical compositions.Type: GrantFiled: July 11, 2007Date of Patent: March 6, 2012Assignee: Wyeth LLCInventors: Daniel R. Lasko, Stephan M. Koza
-
Publication number: 20120053241Abstract: The present invention relates to an aqueous nanoemulsion composition comprising conjugated linoleic acid. More particularly, the present invention relates to an aqueous nanoemulsion composition comprising 5 to 50 wt % of conjugated linoleic acid, 0.01 to 5 wt % of lecithin, 0.01 to 5 wt % of ethanol as a dissolution aid, 1 to 15 wt % of coemulsifier, 10 to 40 wt % of glycerine and the balance of water.Type: ApplicationFiled: February 19, 2010Publication date: March 1, 2012Applicants: Hwail Pharmaceutical Co., Ltd.Inventors: Hyo Gyoung Yu, Hong Geun Ji, Hye Kyeong Woo, Soo Dong Kim
-
Publication number: 20120045835Abstract: The present invention relates to a portable device for the detection of analytes, in particular toxic substances, comprising at least a whole-cell biosensor with cells immobilized onto a transparent and inert matrix that allows the maintenance of cell vitality. The matrix comprises a mixture of collagen and/or its enzyme degradation derivatives, a proteoglycan and a mixture of vinyl polymer and an optionally modified polysiloxane, and an orthosilicate. The biosensor can be a genetically modified cell that expresses luciferase as reporter gene.Type: ApplicationFiled: February 11, 2010Publication date: February 23, 2012Inventors: Elisa Michelini, Aldo Roda, Luisa Stella Dolci, Luca Cevenini, Laura Mezzanotte
-
Publication number: 20120045836Abstract: The present invention is generally in the field of continuous and high-cell-density cultivation in laboratory- or large-scale liquid shaken cultures. More particularly it relates to a method of enzyme-based fed-batch (EnBase) for liquid microbial prokaryotic or eukaryotic cell cultivation having the possibility to manipulate the growth rate of the cultured organisms by a controlled enzymatic release of the growth-limiting substrate-monomer from substrate-polymers or substrate-oligomers.Type: ApplicationFiled: March 4, 2010Publication date: February 23, 2012Applicant: BIOSILTA OYInventors: Peter Neubauer, Antje Neubauer, Antii Vasala
-
Patent number: 8119403Abstract: The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising a three-dimensional matrix comprising lymphoid tissue, a three-dimensional matrix comprising epithelial and/or endothelial cells, and diseased cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals.Type: GrantFiled: March 5, 2010Date of Patent: February 21, 2012Assignee: Sanofi Pasteur Vaxdesign Corp.Inventors: William L. Warren, Russell Higbee, Eric Mishkin, Guzman Sanchez-Schmitz, Heather Fahlenkamp, Michael Rivard
-
Publication number: 20120034696Abstract: Particular aspects provide compositions comprising an electrokinetically altered oxygenated aqueous fluid, wherein the oxygen in the fluid is present in an amount of at least 25 ppm. In certain aspects, the electrokinetically altered oxygenated aqueous fluid comprises electrokinetically modified or charged oxygen species present in an amount of at least 0.5 ppm. In certain aspects the electrokinetically altered oxygenated aqueous fluid comprises solvated electrons stabilized by molecular oxygen, and wherein the solvated electrons present in an amount of at least 0.01 ppm. In certain aspects, the fluid facilitates oxidation of pyrogallol to purpurogallin in the presence of horseradish peroxidase enzyme (HRP) in an amount above that afforded by a control pressure pot generated or fine-bubble generated aqueous fluid having an equivalent dissolved oxygen level, and wherein there is no hydrogen peroxide, or less than 0.1 ppm of hydrogen peroxide present in the electrokinetic oxygen-enriched aqueous fluid.Type: ApplicationFiled: January 28, 2011Publication date: February 9, 2012Applicant: Revalesio CorporationInventors: Anthony B. Wood, Gregory J. Archambeau, Richard L. Watson
-
Publication number: 20120028353Abstract: The present invention relates to precursor cells to hepatic stellate cells, compositions comprising same and methods of isolating same. The surface antigenic profile of the precursors is MHC class Ia negative, ICAM-1+, VCAM-1+, ?3-integrin+. In addition to expression of these surface markers, the cells also express the intracellular markers desmin, vimentin, smooth muscle ?-actin, nestin, hepatocyte growth factor, stromal derived factor-1? and Hlx homeobox transcriptional factor.Type: ApplicationFiled: October 13, 2010Publication date: February 2, 2012Inventors: Hiroshi Kubota, Lola M. Reid
-
Patent number: 8105491Abstract: An extracorporeal filtration and detoxification system and method generally comprise separating ultrafiltrate from cellular components of blood, treating the ultrafiltrate independently of the cellular components in a recirculation circuit, recombining treated ultrafiltrate and the cellular components, and returning whole blood to the patient. A recirculation circuit generally comprises an active cartridge including active cells operative to effectuate a selected treatment; in some embodiments, the active cells are the C3A cell line.Type: GrantFiled: February 23, 2005Date of Patent: January 31, 2012Assignee: Vital Therapies, Inc.Inventors: John D. Brotherton, Dar He
-
Publication number: 20120021063Abstract: To provide a collagen/elastin crosslinked material capable of satisfactorily corresponding to various uses such as medical materials including an artificial dermis and scaffolding materials for cell culture. The collagen/elastin crosslinked material is obtained by crosslinking a fish-derived collagen and a fish-derived elastin, and is fully capable of corresponding to various uses such as medical materials including an artificial dermis and scaffold material for cell culture.Type: ApplicationFiled: March 10, 2010Publication date: January 26, 2012Applicants: MARUHA NICHIRO FOODS, INC., HIROSAKI UNIVERSITY, SAPPORO MEDICAL UNIVERSITYInventors: Yoshitaka Matsumoto, Takatoshi Yotsuyanagi, Shinichi Suto, Yoshifumi Yamaya, Yosuke Hoshino, Kazunari Nishimura, Tomoko Koga, Hiroyuki Enari
-
Publication number: 20120021459Abstract: The invention provides stable feed media containing pyruvate and methods for stabilizing feed media by adding pyruvate. The invention further provides methods for producing proteins using such media and proteins produced through the use of such methods.Type: ApplicationFiled: September 26, 2011Publication date: January 26, 2012Applicant: Amgen Inc.Inventors: Arvia Eleanor Morris, Aurora Villegas Viaje, Erika Pineda